Hepatitis B and Delta Virus Are Prevalent but Often Subclinical Co-Infections among HIV Infected Patients in Guinea-Bissau, West Africa: A Cross-Sectional Study
Background Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) may lead to accelerated hepatic disease progression with higher rates of liver cirrhosis and liver-related mortality compared with HBV mono-infection. Co or super-infection with hepatitis Delta virus (HDV) may worsen the liver disease and complicate treatment possibilities. Methods In this cross-sectional study we included HIV-infected individuals who had a routine blood analysis performed at an HIV clinic in Bissau, Guinea-Bissau between the 28th of April and 30th of September 2011. All patients were interviewed, had a clinical exam performed and had a blood sample stored. The patients' samples were tested for HBV and HDV serology, and HBV/HDV viral loads were analyzed using in-house real-time PCR methods. Results In total, 576 patients (417 HIV-1, 104 HIV-2 and 55 HIV-1/2) were included in this study. Ninety-four (16.3%) patients were HBsAg positive of whom 16 (17.0%) were HBeAg positive. In multivariable logistic regression analysis, CD4 cell count <200 cells/ μl and animist religion were significantly associated with HBsAg positivity. Due to scarcity of available plasma, virological analyses were not performed for eight patients. HBV DNA was detected in 42 of 86 samples (48.8%) positive for HBsAg and genotyping was performed in 26 patients; 25 of whom had genotype E and one genotype D. Among 9 patients on antiretroviral treatment (ART), one patient had the [L180M, M204V] mutation associated with lamivudine resistance. Among the HBsAg positive patients 25.0% were also positive for anti-HDV and 4/9 (44.4%) had detectable HDV RNA. Conclusion HBV and HDV were frequent co-infections among HIV positive patients in Guinea-Bissau and chronic infection was associated with severe immunosuppression. Lamivudine was widely used among HBsAg positive patients with the risk of developing resistant HBV.
References
[1]
Ari？n KK, Abraha A, Qui？ones-Mateu ME, Kestens L, Vanham G, et al. (2005) The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 79: 8979–8990. doi: 10.1128/jvi.79.14.8979-8990.2005
[2]
Rowland-Jones SL, Whittle HC (2007) Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nat Immunol 8: 329–331. doi: 10.1038/ni0407-329
[3]
Da Silva ZJ, Ines Oliveira, Andersen A, Dias F, Rodrigues A, et al. (2008) Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 dissapering? AIDS 22: 1195–1202. doi: 10.1097/qad.0b013e328300a33d
[4]
Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, et al. (2005) A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34: 1329–1339.
[5]
Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97–107. doi: 10.1046/j.1365-2893.2003.00487.x
[6]
Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44: S6–9. doi: 10.1016/j.jhep.2005.11.004
[7]
Dumpis U, Holmes EC, Mendy M, Hill A, Thursz M, et al. (2001) Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. J Hepatol 35: 99–104. doi: 10.1016/s0168-8278(01)00064-2
[8]
Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4–66. doi: 10.1016/s0959-8049(02)00739-6
[9]
Dupinay T, Restorp K, Leutscher P, Rousset D, Chemin I, et al. (2010) High prevalence of hepatitis B virus genotype E in Northern Madagascar indicates a West-African lineage. J Med Virol 82: 1515–1526. doi: 10.1002/jmv.21865
[10]
Mulders MN, Venard V, Njayou M, Edorh AF, Bola Oyefolu AO, et al. (2004) Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West Africa. J Infect Dis 190: 400–408. doi: 10.1086/421502
[11]
Lin CL, Kao JH (2011) The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 26: 123–130. doi: 10.1111/j.1440-1746.2010.06541.x
[12]
Kramvis A, Kew MC (2007) Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatology Research 37: 9–19. doi: 10.1111/j.1872-034x.2007.00098.x
[13]
Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, et al. (2005) Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV–HBV International Panel. AIDS 19: 221–240. doi: 10.1097/01.aids.0000163948.62176.e7
[14]
Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921–1926. doi: 10.1016/s0140-6736(02)11913-1
[15]
Puoti M, Torti C, Bruno R, Filice G, Carosi G (2006) Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44: S65–70. doi: 10.1016/j.jhep.2005.11.015
[16]
Bodsworth N, Donovan B, Nightingale BN (1989) The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 160: 577–582. doi: 10.1093/infdis/160.4.577
[17]
Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, et al. (2005) Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19: 593–601. doi: 10.1097/01.aids.0000163936.99401.fe
[18]
Hoffman CJ, Thio CL (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7: 402–409. doi: 10.1016/s1473-3099(07)70135-4
[19]
Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, et al. (1999) Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30: 1302–1306. doi: 10.1002/hep.510300525
[20]
Stewart B, Jobarteh ML, Sarge-Njie R, Alabi A, de Silva T, et al. (2011) Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa. BMC Res Notes 4: 561. doi: 10.1186/1756-0500-4-561
[21]
Hamer RL, Zaaijer HL, Wallis CL, Siwale M, Ive F, et al. (2013) HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Defic Syndr 64: 174–182. doi: 10.1097/qai.0b013e3182a60f7d
[22]
Bado G, Penot P, N'Diaye MD, Amiel C, Hema A, et al. (2013) Hepatitis B seroprevalence in HIV-infected patients consulting in a public day care unit in Bobo Dioulasso, Burkina Faso. Med Mal Infect 43: 202–207. doi: 10.1016/j.medmal.2013.04.001
[23]
Farci P (2003) Delta hepatitis: an update. J Hepatol 39: S212–219. doi: 10.1016/s0168-8278(03)00331-3
[24]
Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7: 31–40. doi: 10.1038/nrgastro.2009.205
[25]
Hughes SA, Wedemeyer H, Harrison PM (2011) Hepatitis delta virus. Lancet 378: 73–85. doi: 10.1016/s0140-6736(10)61931-9
[26]
Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, et al. (2006) Eighth major clade for hepatitis delta virus. Emerg Infect Dis 12: 1447–50. doi: 10.3201/eid1209.060112
[27]
H？nge BL, Jespersen S, Nordentoft PB, Medina C, da Silva D, et al.. (2013) Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV infected patients in Guinea-Bissau: a seven year retrospective cohort study. BMJ Open 3e003499.
[28]
H？nge BL, Bjarnason MPO, Jespersen S, Medina C, Té DS, et al. (2013) Performance of three rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa. J Acquir Immune Defic Syndr 65: 87–90. doi: 10.1097/qai.0b013e3182a97b81
[29]
Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, et al. (2010) Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52: 508–513. doi: 10.1016/j.jhep.2010.01.007
[30]
Krarup HB, Andersen S, Madsen PH, Okkels H, Hvingel BH, et al. (2008) Benign course of long-standing hepatitis B virus infection among Greenland Inuit? Scand J Gastroenterol 43: 334–343. doi: 10.1080/00365520701712198
[31]
Krarup H, Andersen S, Madsen PH, Christensen PB, Laursen AL, et al. (2011) HBeAg and not genotype predicts viral load in patients with hepatitis B in Denmark: A nationwide cohort study. Scand J Gastroenterol 46: 1484–1491. doi: 10.3109/00365521.2011.619273
[32]
B？rresen ML, Olsen OR, Ladefoged K, McMahon BJ, Hjuler T, et al. (2010) Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland. J Viral Hepat 17: 162–170. doi: 10.1111/j.1365-2893.2009.01159.x
[33]
Rouet F1, Chaix ML, Inwoley A, Msellati P, Viho I, et al. (2004) HBV and HCV Prevalence and Viraemia in HIV-Positive and HIV-Negative Pregnant Women in Abidjan, C？te d'Ivoire: The ANRS 1236 Study. J Med Virol 74: 34–40. doi: 10.1002/jmv.20143
[34]
Jobarteh M, Malfroy M, Peterson I, Jeng A, Sarge-Njie R, et al. (2010) Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J 7: 230. doi: 10.1186/1743-422x-7-230
[35]
Sagoe KWC, Agyei AA, Ziga F, Lartey M, Adiku TK, et al. (2012) Prevalence and Impact of Hepatitis B and C Virus Co-Infections in Antiretroviral Treatment Na？ve Patients With HIV Infection at a Major Treatment Center in Ghana. J Med Virol 84: 6–10. doi: 10.1002/jmv.22262
[36]
Idoko J, Meloni S, Muazu1 M, Nimzing L, Badung B, et al (2009) Impact of Hepatitis B Virus Infection on Human Immunodeficiency Virus Response to Antiretroviral Therapy in Nigeria. Clin Infect Dis 49: 1268–1273. doi: 10.1086/605675
[37]
Diop-Ndiaye H, Touré-Kane C, Etard JF, L？ G, Diaw PA, et al. (2008) Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation. J Med Virol 80: 1332–1336. doi: 10.1002/jmv.21236
[38]
Bodsworth N, Donovan B, Nightingale BN (1989) The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 160: 577–582. doi: 10.1093/infdis/160.4.577
[39]
Bani-Sadr F, Maillard A, Ponscarme D, Scieux C, Molina JM (2003) Reactivation of HBV replication in HIV-HBV infected patients. Am J Med 114: 768–9. doi: 10.1016/s0002-9343(03)00156-6
[40]
Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, et al. (2011) Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat 18: e212–216. doi: 10.1111/j.1365-2893.2011.01435.x
[41]
Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert TF, et al. (2009) Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World J Gastroenterol 15: 753–5. doi: 10.3748/wjg.15.753
[42]
Suzuki S, Sugauchi F, Orito E, Kato H, Usuda S, et al. (2003) Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in the C？te d'Ivoire: complete genome sequence and phylogenetic relatedness of HBV genotype E. J Med Virol 69: 459–465. doi: 10.1002/jmv.10331
[43]
Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, et al. (2013) Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS One 8: e61297. doi: 10.1371/journal.pone.0061297
[44]
Bacha A, Roingeard P, Coll AM, Essex M, M'Boup S (1990) Hepatitis delta virus antibodies in hepatitis B surface antigen asymptomatic carriers in Senegal. J Infect Dis 161: 150–151. doi: 10.1093/infdis/161.1.150
[45]
Onyekwere CA, Audu RA, Duro-Emmanuel F, Ige FA (2012) Hepatitis D infection in Nigeria. Indian J Gastroenterol 31: 34–5. doi: 10.1007/s12664-011-0158-9
[46]
Mansour W, Malick FZ, Sidiya A, Ishagh E, Chekaraou MA, et al. (2012) Prevalence, risk factors, and molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in Mauritania. J Med Virol 84: 1186–98. doi: 10.1002/jmv.23336
[47]
Lunel-Fabiani F, Mansour W, Amar AO, Aye M, Le Gal F, et al. (2013) Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: A cross sectional study. J Infect 67: 448–57. doi: 10.1016/j.jinf.2013.06.008
[48]
Boyd A, Lacombe K, Miailhes P, Gozlan J, Bonnard P, et al. (2010) Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 17: 65–76. doi: 10.1111/j.1365-2893.2009.01153.x
